J Cerebrovasc Endovasc Neurosurg.  2023 Dec;25(4):380-389. 10.7461/jcen.2023.E2023.05.003.

Safety of middle meningeal artery embolization for treatment of subdural hematoma: A nationwide propensity score matched analysis

• McCann CP
• Brandel MG
• Wali AR
• Steinberg JA
• Pannell JS
• Santiago-Dieppa DR
• Khalessi AA

• KMID: 2549443
• DOI: http://doi.org/10.7461/jcen.2023.E2023.05.003

Abstract

Objective
Middle meningeal artery embolization (MMAe) has burgeoned as a treatment for chronic subdural hematoma (cSDH). This study evaluates the safety and short-term outcomes of MMAe patients relative to traditional treatment approaches.
Methods
In this retrospective large database study, adult patients in the National Inpatient Sample from 2012-2019 with a diagnosis of cSDH were identified. Cost of admission, length of stay (LOS), discharge disposition, and complications were analyzed. Propensity score matching (PSM) was utilized.
Results
A total of 123,350 patients with cSDH were identified: 63,450 without intervention, 59,435 surgery only, 295 MMAe only, and 170 surgery plus MMAe. On PSM analysis, MMAe did not increase the risk of inpatient complications or prolong the length of stay compared to conservative management (p>0.05); MMAe had higher cost ($31,170 vs. $10,768, p<0.001) than conservative management, and a lower rate of nonroutine discharge (53.8% vs. 64.3%, p=0.024). Compared to surgery, MMAe had shorter LOS (5 vs. 7 days, p<0.001), and lower rates of neurological complications (2.7% vs. 7.1%, p=0.029) and nonroutine discharge (53.8% vs. 71.7%, p<0.001). There was no significant difference in cost (p>0.05).
Conclusions
MMAe had similar LOS and decreased odds of adverse discharge with a modest cost increase compared to conservative management. There was no difference in inpatient complications. Compared to surgery, MMAe treatment was associated with decreased LOS and rates of neurological complications and nonroutine discharge. This nationwide analysis supports the safety of MMAe to treat cSDH.

Keyword

Chronic subdural hematoma; Middle meningeal artery embolization; Outcomes; Complications; Craniotomy

Reference

1. Agency for Healthcare Research and Quality. HCUP National Inpatient Sample (NIS). in (HCUP) HCaUP. Rockville, MD: 2012-2019.

2. Aspegren OP, Åstrand R, Lundgren MI, Romner B. Anticoagulation therapy a risk factor for the development of chronic subdural hematoma. Clin Neurol Neurosurg. 2013; Jul. 115(7):981–4.

3. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015; Nov. 123(5):1209–15.

4. Dicpinigaitis AJ, Al-Mufti F, Cooper JB, Kazim SF, Couldwell WT, Schmidt MH, et al. Nationwide trends in middle meningeal artery embolization for treatment of chronic subdural hematoma: A population-based analysis of utilization and short-term outcomes. J Clin Neurosci. 2021; Dec. 94:70–5.

5. Dobran M, Marini A, Nasi D, Liverotti V, Benigni R, Costanza MD, et al. Clinical outcome of patients over 90 years of age treated for chronic subdural hematoma. J Korean Neurosurg Soc. 2022; Jan. 65(1):123–9.

6. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; Jan. 36(1):8–27.

7. Han MH, Ryu JI, Kim CH, Kim JM, Cheong JH, Yi HJ. Predictive factors for recurrence and clinical outcomes in patients with chronic subdural hematoma. J Neurosurg. 2017; Nov. 127(5):1117–25.

8. Holl DC, Volovici V, Dirven CMF, Peul WC, van Kooten F, Jellema K, et al. Pathophysiology and nonsurgical treatment of chronic subdural hematoma: From past to present to future. World Neurosurg. 2018; Aug. 116:402–11.

9. Ironside N, Nguyen C, Do Q, Ugiliweneza B, Chen CJ, Sieg EP, et al. Middle meningeal artery embolization for chronic subdural hematoma: A systematic review and meta-analysis. J Neurointerv Surg. 2021; Oct. 13(10):951–7.

10. Joyce E, Bounajem MT, Scoville J, Thomas AJ, Ogilvy CS, Riina HA, et al. Middle meningeal artery embolization treatment of nonacute subdural hematomas in the elderly: A multiinstitutional experience of 151 cases. Neurosurg Focus. 2020; Oct. 49(4):e5.

11. Khera R, Angraal S, Couch T, Welsh JW, Nallamothu BK, Girotra S, et al. Adherence to methodological standards in research using the national inpatient sample. JAMA. 2017; Nov. 318(20):2011–18.

12. Knopman J, Link TW, Navi BB, Murthy SB, Merkler AE, Kamel H. Rates of repeated operation for isolated subdural hematoma among older adults. JAMA Netw Open. 2018; Oct. 1(6):e183737.

13. Lakomkin N, Graffeo CS, Hadjipanayis CG. Specific causes and predictors of readmissions following acute and chronic subdural hematoma evacuation. J Clin Neurosci. 2020; May. 75:35–9.

14. Nia AM, Srinivasan VM, Lall RR, Kan P. Middle meningeal artery embolization for chronic subdural hematoma: A national database study of 191 patients in the United States. World Neurosurg. 2021; Sep. 153:e300–7.

15. Nouri A, Gondar R, Schaller K, Meling T. Chronic Subdural Hematoma (cSDH): A review of the current state of the art. Brain Spine. 2021; Nov. 1:100300.

16. Rauhala M, Helén P, Seppä K, Huhtala H, Iverson GL, Niskakangas T, et al. Long-term excess mortality after chronic subdural hematoma. Acta Neurochir (Wien). 2020; Jun. 162(6):1467–78.

17. Rauhala M, Luoto TM, Huhtala H, Iverson GL, Niskakangas T, Öhman J, et al. The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. J Neurosurg. 2019; Mar. 132(4):1147–57.

18. Srivatsan A, Mohanty A, Nascimento FA, Hafeez MU, Srinivasan VM, Thomas A, et al. Middle meningeal artery embolization for chronic subdural hematoma: Meta-analysis and systematic review. World Neurosurg. 2019; Feb. 122:613–9.

19. Takizawa K, Sorimachi T, Ishizaka H, Osada T, Srivatanakul K, Momose H, et al. Enlargement of the middle meningeal artery on MR angiography in chronic subdural hematoma. J Neurosurg. 2016; Jun. 124(6):1679–83.

20. Weigel R, Schilling L, Krauss JK. The pathophysiology of chronic subdural hematoma revisited: Emphasis on aging processes as key factor. Geroscience. 2022; Jun. 44(3):1353–71.

21. Yoshihara H, Yoneoka D. Understanding the statistics and limitations of large database analyses. Spine (Phila Pa 1976). 2014; Jul. 39(16):1311–2.